Valeant (VRX) PT, Estimates Cut at BMO Capital; Remains on the Sidelines

November 3, 2015 8:18 AM

BMO Capital analyst Alex Arfaei cut estimates and his price target on Valeant Pharmaceuticals (NYSE: VRX) to $133.00 (from $141.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found